Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andreas Helke who wrote (11233)	11/16/1997 1:58:00 PM
From: Andrew H	Respond to of 32384

>>I expect a major move up in anticipation of Ligands first NDA but it might be off a lesser percentage than the Agouron move because the drug is likely to be less of a blockbuster than Viracept was. But many of the biotechs with approved drugs have market caps in the billion dollar range even if I don't see that big of a market for their drug. << Andreas, don't forget that Panretin has shown considerable efficacy for psoriasis (a disease which affects 6MM Americans). Phase 2 trials showed excellent results and P3 should begin any time. While Panretin will be first approved for the KS indication (something like 35K?) which does have a relatviely small market, the psoriasis market will be about 170 times as large as the KS market in the US.